Epidemiology and risk factors associated with Hodgkin´s lymphoma

Czech version

Authors: H. Mociková
Authors‘ workplace: Interní hematologická klinika, FN Královské Vinohrady Praha a 3. lékařská fakulta Univerzity Karlovy v Praze
Published in: Transfuze Hematol. dnes,20, 2014, No. 3, p. 81-86.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

The incidence of Hodgkin´s lymphoma is 2.5 cases/100 000 inhabitants per year in the Czech Republic and it occurs more frequently in males compared to females-1.3 : 1. No causal etiopathogenetic factor responsible for Hodgkin´s lymphoma has been identified so far. This review summarizes risk factors that are associated with the occurrence of Hodgkin´s lymphoma. The significance of these factors and the way they affect the incidence of Hodgkin´s lymphoma remains under investigation.

Key words:
Hodgkin´s lymphoma, epidemiology, risk factors

Sources

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893 2917.

2. Glaser SL, Swartz WG. Time trends in Hodgkin's disease incidence. The role of diagnostic accuracy. Cancer 1990; 66: 2196-2204.

3. Ries LA G, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review; 1973-1994. NIH publ. no. 97-2789. Bethesda: National Cancer Institute, 1997.

4. Stein H, Delsol G, Pileri SA, et al. Classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al. (Eds): WHO classification of tumours of haemopoietic and lymphoid tissues. IARC: Lyon 2008: 326-334.

5. Sjöberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood 2012; 119: 990-996.

6. Pulte D, Jansen L, Gondos A, et al. GEKID Cancer Survival Working Group. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol 2014; 164: 851-817.

7. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70: 375-382.

8. Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest 2012 1; 122: 3439-3447.

9. Batlevi CL, Younes A: Novel therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2013; 2013: 394-399.

10. Blum KA, Johnson JL, Niedzwiecki D, et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007; 48: 1313-1319.

11. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006; 107: 1731-1732.

12. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 1324-1332.

13. Goldin LR, Björkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146: 91-94.

14. Robertson SJ, Lowman JT, Grufferman S, et al. Familial Hodgkin's disease. A clinical and laboratory investigation. Cancer 1987; 59: 1314-1319.

15. Grufferman S, Cole P, Smith PG, Lukes RJ. Hodgkin's disease in siblings. N Engl J Med 1977; 296: 248-250.

16. Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 1995; 332: 413-418.

17. Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin’s lymphoma. Blood 2004; 103: 3216-3221.

18. Cozen W, Gill PS, Salam MT, et al. Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin’s lymphoma. Blood 2008; 111: 3377-3382.

19. Glaser SL, Gulley ML, Clarke CA, et al. Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. Int J Cancer 2008; 123: 1499-1507.

20. Huang X, Kushekhar K, Nolte I, et al. HLA associations in classical Hodgkin lymphoma: EBV status matters. PLoS One 2012; 7(7): e39986. doi: 10.1371/journal.pone.0039986. Epub 2012 Jul 10.

21. Cozen W, Li D, Best T, et al. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood 2012; 119: 469-475.

22. Yri OE, Ekstrøm PO, Hilden ,Vet al. Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma. Leuk Lymphoma 2012; 53: 1934-1944.

23. Havranek O, Spacek M, Hubacek P, et al. Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma. Neoplasma 2011; 58: 392-395.

24. Au WY, Gascoyne RD, Gallagher RE, et al. Hodgkin’s lymphoma in Chinese migrants to British Columbia: a 25-year survey. Ann Oncol 2004; 15: 626-630.

25. Varghese C, Barrett JH, Johnston C, et al. High risk of lymphomas in children of Asian origin: ethnicity or confounding by socioeconomic status? Br J Cancer 1996; 74: 1503-1505.

26. Ruiz M, Parsons C, Cole J. Characterization of HIV-associated Hodgkin's lymphoma in HIV-infected patients: a single-center experience. J Int Assoc Provid AIDS Care (Chic) 2012; 11: 234-238.

27. Siddon A, Lozovatsky L, Mohamed A, et al. Human herpesvirus 6 positive Reed-Sternberg cells in nodular sclerosis Hodgkin lymphoma. Br J Haematol 2012; 158: 635-643.

28. Anderson LA, Atman AA, McShane CM, et al. Common infection-related conditions and risk of lymphoid malignancies in older individuals. Br J Cancer 2014; 110: 2796-2803.

29. Bierman PJ, Vose JM, Langnas AN, et al. Hodgkin's disease following solid organ transplantation. Ann Oncol 1996; 7: 265-270.

30. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol 1999; 17: 3122-3127.

31. Fallah M, Liu X, Ji J, et al. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann Oncol 2014 Apr 8. doi: 10.1093/annonc/mdu144.

32. Zablotska LB, Lane RS, Frost SE, et al. Leukemia, lymphoma and multiple myeloma mortality (1950-1999) and incidence (1969-1999) in the Eldorado uranium workers cohort. Environ Res 2014; 130: 43-50.

33. Kamper-Jørgensen M, Rostgaard K, Glaser SL, et al. Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Ann Oncol 2013; 24: 2245-2255.

34. Chang ET, Zheng T, Weir EG, et al. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 2004; 96: 305-315.

35. Monnereau A, Glaser SL, Schupp CW, et al. Exposure to UV radiation and risk of Hodgkin lymphoma: a pooled analysis. Blood 2013; 122: 3492-3499.

36. Smedby KE, Hjalgrim H, Melbye M, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst 2005; 97: 199-209.

37. Tramacere I, Pelucchi C, Bonifazi M, et al. A meta-analysis on alcohol drinking and the risk of Hodgkin lymphoma. Eur J Cancer Prev 2012; 21: 268-273.